Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex  >  All News

News : Economy & Forex
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies / ForexCryptocurrenciesEconomic EventsPress releases

Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

share with twitter share with LinkedIn share with facebook
06/26/2020 | 04:33am EDT
A car is driven past an AstraZeneca site in Macclesfield

Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan.

The discussion follows a flurry of supply deals signed by the British drug maker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment.

Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan. AstraZeneca said separately that it is in talks with the Japanese government on supplies of the potential vaccine, known as AZD1222.

Chief Cabinet Secretary Yoshihide Suga said earlier on Friday that the government is supporting domestic vaccine development but is also in negotiations with other parties.

"In any event, the government will work hard to ensure that Japan has the vaccines it needs," Suga said.

In Japan, AnGes Inc and Osaka University are working on a DNA vaccine for the novel coronavirus. Shionogi & Co is working on a recombinant protein type, while the University of Tokyo and Daiichi Sankyo are developing an mRNA version.

AstraZeneca has doubled manufacturing and supply capacity for its potential vaccine to over 2 billion doses.

There are currently no approved vaccines or treatments for the illness caused by the new coronavirus, but about a dozen vaccines from more than 100 candidates globally are being tested in humans.

(Reporting by Rocky Swift; Editing by Christian Schmollinger, Kirsten Donovan)

Stocks mentioned in the article
ChangeLast1st jan.
ANGES, INC. 3.31% 1560 End-of-day quote.144.13%
ASTRAZENECA PLC 1.42% 8568 Delayed Quote.11.08%
DAIICHI SANKYO COMPANY, LIMITED 0.50% 9371 End-of-day quote.29.65%
SANKYO CO., LTD. 3.60% 2789 End-of-day quote.-23.06%
SHIONOGI & CO., LTD. 0.68% 6084 End-of-day quote.-10.09%
share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
08:28aRFA RENEWABLE FUELS ASSOCIATION : Supports White House Consideration of Reciprocal Tariffs on Imports of Brazilian Ethanol
PU
08:24aUK pensions group seeks ban on new petrol, diesel and hybrid cars by 2025
RE
08:18aMonetary Policy Reports – July 2020
PU
08:18aInflation Outlook and Analysis Report – July 2020
PU
08:18aFiscal Developments Report – July 2020
PU
08:18aBANK OF GHANA : Real Sector Developments Report – July 2020
PU
08:12aBrazil can live with record debt, deficits despite the noise
RE
07:59aFROM CARATS TO PEANUTS : how a pandemic upended the global diamond industry
RE
07:38aSOUTH AFRICAN RESERVE BANK : Prudential Authority to appeal judgement
PU
07:35aGhana's inflation rises to 11.4% in July
RE
Latest news "Economy & Forex"